07 April 2021 | NewsUpcoming webinar: COVID-19 vaccine uptake and acceptanceRead the full article
This new NCIRS resource provides a general guide for healthcare providers to facilitate effective communication about meningococcal B (Men B) vaccination. The resource has a focus on Aboriginal and Torres Strait Islander children.
Under the National Immunisation Program changes that came into effect from 1 July 2020, MenB vaccine (Bexsero) is now funded for all Aboriginal and Torres Strait Islander children from 2 months of age. A catch-up program is also available for Aboriginal and Torres Strait Islander children aged <2 years (i.e. up to 23 months) until June 2023.
The incidence of MenB disease is 4 times higher in Aboriginal and Torres Strait Islander children aged <2 years than non-Indigenous children of the same age. The vaccine is funded to reduce the burden of disease in young Aboriginal and Torres Strait Islander children.
MenB vaccine is also funded for all people of any age with certain specified medical risk conditions which put them at higher risk of MenB disease.
Meningococcal disease is a serious illness that can cause disability and death. Vaccination is a safe and effective way to protect against this disease.
Access the resource here
NCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433 | Fax (612) 9845 1418 | ABN 53 188 579 090
We acknowledge that the National Centre for Immunisation Research and Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.
Copyright © 2021 NCIRS. All rights reserved
Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.
Stay updated with the latest from NCIRS